Invention Grant
- Patent Title: Enhancer of Zeste Homolog 2 inhibitors
- Patent Title (中): Zeste同源2抑制剂的增强剂
-
Application No.: US14651711Application Date: 2013-12-12
-
Publication No.: US09382234B2Publication Date: 2016-07-05
- Inventor: Steven David Knight , William Henry Miller , Kenneth Allen Newlander , Carla A. Donatelli
- Applicant: GlaxoSmithKline LLC
- Applicant Address: US DE Wilmington, New Castle
- Assignee: GlaxoSmithKline LLC
- Current Assignee: GlaxoSmithKline LLC
- Current Assignee Address: US DE Wilmington, New Castle
- Agent Duke M. Fitch; Kathryn A. Lutomski; Edward R. Gimmi
- International Application: PCT/US2013/074558 WO 20131212
- International Announcement: WO2014/107277 WO 20140710
- Main IPC: C07D405/14
- IPC: C07D405/14 ; C07D309/38 ; C07D401/14 ; C07D213/68 ; C07D401/12 ; C07D405/12 ; C07D213/73 ; C07D409/12
Abstract:
This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
Public/Granted literature
- US20150307480A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS Public/Granted day:2015-10-29
Information query
